RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
Vascular Biogenics Stock

Vascular Biogenics Stocks 2025

Vascular Biogenics Stocks

2.22 M

Ticker

VBLT

ISIN

IL0011327454

WKN

A119YE

In 2025, Vascular Biogenics had 2.22 M outstanding stocks, a 0% change from the 2.22 M stocks in the previous year.

The Vascular Biogenics Stocks history

YEARNUMBER OF STOCKS (undefined USD)
2026e2.22
2025e2.22
2024e2.22
2023e2.22
20222.22
20211.9
20201.25
201935.88
201832.97
201727.4
201624.97
201520.31
201418.54
201318.54
201218.54

Vascular Biogenics shares outstanding

The number of shares was Vascular Biogenics in 2024 — This indicates how many shares 2.216 M is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Number of stocks
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Vascular Biogenics earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Vascular Biogenics's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Vascular Biogenics’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Vascular Biogenics's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Vascular Biogenics Aktienanalyse

What does Vascular Biogenics do?

Vascular Biogenics Ltd (VBL) is a biopharmaceutical company that was founded in 2000. The company is headquartered in Modi'in, Israel and is listed on the NASDAQ under the ticker symbol "VBLT". The history of VBL dates back to the discovery of a protein called Vascular Endothelial Growth Factor-B (VEGF-B) by the company's founder, Professor Moshe Deutsch. VEGF-B is considered a key regulator in blood vessel formation and diseases such as cancer, macular degeneration, and arteriosclerosis. VBL's business model is based on the development and commercialization of novel therapies based on the use of VEGF-B. The company focuses on the development of cancer therapies as well as the treatment of eye diseases and inflammatory diseases. VBL is divided into three divisions: 1. Oncology: In this division, VBL is developing a novel therapy for the treatment of cancer based on a encapsulated version of VEGF-B. This therapy aims to slow tumor growth and activate the patient's immune system to fight the tumor. VBL currently has several ongoing clinical trials that show promising results. 2. Ophthalmology: In this division, VBL is investigating the use of VEGF-B in the treatment of macular degeneration, an eye disease that can lead to vision loss. The company has developed a drug called "VB-421" that has been successfully tested in clinical trials. 3. Inflammatory diseases: VBL is also working on the development of therapies for inflammatory diseases such as rheumatism and colitis. The company also uses the VEGF-B active ingredient for this purpose. In recent years, VBL has already brought several drugs to the market and is continuously working on the development of new therapies. The company collaborates closely with various universities and research institutions. Overall, VBL has achieved promising results in research in recent years and has conducted numerous successful clinical trials. The company focuses on the development of therapies for severe diseases for which there is currently no effective treatment. VBL aims to improve the lives of patients worldwide and make great progress in medicine. Vascular Biogenics ist eines der beliebtesten Unternehmen auf Eulerpool.com.

Stocks Details

Evaluating Vascular Biogenics's Shares Outstanding

Vascular Biogenics's shares outstanding refer to the total number of shares that are currently held by all its shareholders, including institutional investors and restricted shares held by the company’s officers and insiders. The number of shares outstanding is crucial in determining the company's market capitalization and is used by investors to assess the company’s size, financial health, and investment potential.

Year-to-Year Comparison

Tracking the changes in Vascular Biogenics’s shares outstanding over the years can provide investors with insights into the company's financial strategies and market valuation. An increase in shares outstanding can result from actions like issuing new shares, while a decrease can result from buybacks.

Impact on Investments

For investors, understanding Vascular Biogenics’s shares outstanding is essential for evaluating its earnings per share (EPS) and market valuation. A change in the number of shares outstanding can impact the EPS, which is a significant driver of stock prices and investor decisions.

Interpreting Changes in Shares Outstanding

Variances in Vascular Biogenics’s shares outstanding can signal shifts in the company’s financial strategy. An increase may dilute the EPS and share value, indicating potential fundraising or acquisitions. Conversely, a decrease, often due to share buybacks, can enhance share value and indicate the company’s confidence in its financial performance.

Frequently Asked Questions about Vascular Biogenics stock

How many stocks are there of Vascular Biogenics?

The current number of stocks of Vascular Biogenics is 2.22 M undefined.

What does Number of Shares / OutstandingShares mean?

The outstanding shares (or issued shares) of Vascular Biogenics are the total number of shares issued and actively held by shareholders - both external investors and company insiders. However, these must be actual shares. may grant stock options to executives that can be converted into shares.

How has the number of shares of Vascular Biogenics evolved in recent years?

The number of shares of Vascular Biogenics has increased by 0% gestiegen compared to last year.

What does the number of shares mean for investors?

The number of shares outstanding is used to calculate key metrics such as a company's market capitalization, earnings per share (EPS), and cash flow per share (CFPS). The number of outstanding shares of a company is not static and can fluctuate greatly over time.

Why does the number of stocks fluctuate?

There are various factors that can lead to a change. Vascular Biogenics as a company can issue new shares, carry out stock splits or reverse splits.

Does the number of shares have an impact on the performance of Vascular Biogenics?

There is no tangible long-term evidence or study that stocks with a certain number of shares (regardless of Mega/Large/Mid/Small Cap) would yield significantly higher returns than others. There are occasional small studies (limited number of stocks, short investment period) that certain classes outperform or have higher risk, but none of them are 1. conclusive (cause-effect is unclear, experiment is not repeatable) or 2. generalizable (generalization is not possible due to small sample size and time period).

How much dividend does Vascular Biogenics pay?

Over the past 12 months, Vascular Biogenics paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Vascular Biogenics is expected to pay a dividend of 0 USD.

What is the dividend yield of Vascular Biogenics?

The current dividend yield of Vascular Biogenics is .

When does Vascular Biogenics pay dividends?

Vascular Biogenics pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Vascular Biogenics?

Vascular Biogenics paid dividends every year for the past 0 years.

What is the dividend of Vascular Biogenics?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Vascular Biogenics located?

Vascular Biogenics is assigned to the 'Health' sector.

Wann musste ich die Aktien von Vascular Biogenics kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Vascular Biogenics from 8/11/2025 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 8/11/2025.

When did Vascular Biogenics pay the last dividend?

The last dividend was paid out on 8/11/2025.

What was the dividend of Vascular Biogenics in the year 2024?

In the year 2024, Vascular Biogenics distributed 0 USD as dividends.

In which currency does Vascular Biogenics pay out the dividend?

The dividends of Vascular Biogenics are distributed in USD.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

Andere Kennzahlen von Vascular Biogenics

Our stock analysis for Vascular Biogenics Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Vascular Biogenics Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.